# A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination

> **NCT02606877** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 37 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** nintedanib
- **DRUG:** pirfenidone

## Key facts

- **NCT ID:** NCT02606877
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-19
- **Primary completion:** 2017-03-22
- **Final completion:** 2017-03-22
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02606877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02606877, "A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02606877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*